- Home
- IMCC vs MYNZ Comparison
IMCC vs MYNZ Comparison
Compare IMCC & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCC | MYNZ |
|---|---|---|
| Founded | 1980 | 2021 |
| Country | Israel | Germany |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4M | 8.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IMCC | MYNZ |
|---|---|---|
| Price | $1.52 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 280.7K | 197.9K |
| Earning Date | 11-13-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,606,703.00 | $659,935.00 |
| Revenue This Year | $47.12 | N/A |
| Revenue Next Year | $12.83 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.92 | N/A |
| 52 Week Low | $0.93 | $0.92 |
| 52 Week High | $7.12 | $8.20 |
Technical Indicators
Market Signals| Indicator | IMCC | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 53.56 |
| Support Level | $1.39 | $1.00 |
| Resistance Level | $1.91 | $1.15 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 21.74 | 87.76 |
Price Performance
Historical ComparisonAbout IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.